JP6858181B2 - 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ - Google Patents

免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ Download PDF

Info

Publication number
JP6858181B2
JP6858181B2 JP2018516740A JP2018516740A JP6858181B2 JP 6858181 B2 JP6858181 B2 JP 6858181B2 JP 2018516740 A JP2018516740 A JP 2018516740A JP 2018516740 A JP2018516740 A JP 2018516740A JP 6858181 B2 JP6858181 B2 JP 6858181B2
Authority
JP
Japan
Prior art keywords
hgdf
cancer
antibody
gdf
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018516740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535404A (ja
JP2018535404A5 (enExample
Inventor
イェルク・ヴィッシュフーゼン
マルクス・ハーケ
ラインハルト・ドゥマー
マティアス・メーリング
Original Assignee
ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1517527.6A external-priority patent/GB201517527D0/en
Priority claimed from GBGB1607800.8A external-priority patent/GB201607800D0/en
Application filed by ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク filed Critical ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク
Publication of JP2018535404A publication Critical patent/JP2018535404A/ja
Publication of JP2018535404A5 publication Critical patent/JP2018535404A5/ja
Application granted granted Critical
Publication of JP6858181B2 publication Critical patent/JP6858181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018516740A 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ Active JP6858181B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1517527.6A GB201517527D0 (en) 2015-10-02 2015-10-02 GDF-15 as a diagnosis marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB1517527.6 2015-10-02
GB1607800.8 2016-04-29
GBGB1607800.8A GB201607800D0 (en) 2016-04-29 2016-04-29 GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
PCT/EP2016/073519 WO2017055612A1 (en) 2015-10-02 2016-09-30 Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Publications (3)

Publication Number Publication Date
JP2018535404A JP2018535404A (ja) 2018-11-29
JP2018535404A5 JP2018535404A5 (enExample) 2021-01-21
JP6858181B2 true JP6858181B2 (ja) 2021-04-14

Family

ID=57123979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516740A Active JP6858181B2 (ja) 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５

Country Status (10)

Country Link
US (2) US11262360B2 (enExample)
EP (2) EP4321866A3 (enExample)
JP (1) JP6858181B2 (enExample)
KR (1) KR102621034B1 (enExample)
AU (1) AU2016333538B2 (enExample)
CA (1) CA3000290C (enExample)
DK (1) DK3356827T3 (enExample)
ES (1) ES2968226T3 (enExample)
FI (1) FI3356827T3 (enExample)
WO (1) WO2017055612A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900263B1 (en) * 2012-09-26 2019-06-05 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
AU2017269496B2 (en) 2016-05-24 2021-03-25 Novo Nordisk A/S MIC-1 compounds and use thereof
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019060918A1 (en) * 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
KR102164432B1 (ko) 2019-09-18 2020-10-13 한국과학기술원 Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
EP4031562A4 (en) 2019-09-20 2023-11-01 University of Florida Research Foundation, Incorporated DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
KR102238912B1 (ko) 2020-05-27 2021-04-12 한국과학기술원 Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
CN112162097B (zh) * 2020-07-24 2022-04-01 广州医科大学 Gdf1作为评估pd-1单抗治疗效果的生物标志物
CN112698042A (zh) * 2020-12-17 2021-04-23 北京赛诺浦生物技术有限公司 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
CN113252905A (zh) * 2021-05-12 2021-08-13 北京赛诺浦生物技术有限公司 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
KR20230046264A (ko) 2021-09-29 2023-04-05 (주)펜타메딕스 Line-1의 dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
CN115831306A (zh) * 2023-02-23 2023-03-21 北京康博众联电子科技有限公司 一种数据分析装置、方法及计算机存储介质
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
DE60032355T2 (de) 1999-05-17 2007-04-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
SI2441466T1 (sl) 2004-04-13 2015-01-30 St Vincent's Hospital Sydney Limited Centre For Immunology Sredstvo, ki inhibira MIC-1
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
WO2009046495A1 (en) 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
WO2009150256A1 (en) * 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
EP2209003A1 (en) * 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
EP2900263B1 (en) 2012-09-26 2019-06-05 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
EP2934584B1 (en) 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US11021752B2 (en) * 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
JP2015078138A (ja) 2013-10-15 2015-04-23 株式会社ニックス 小動物防除性樹脂組成物
US20160340407A1 (en) * 2014-01-14 2016-11-24 Dana-Farber Camcer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
RS61661B1 (sr) 2014-02-21 2021-04-29 Nektar Therapeutics India Pvt Ltd Il-2rbeta-selektivni agonisti u kombinaciji sa anti-ctla-4 antitelom ili anti-pd-1 antitelom
HRP20231514T1 (hr) 2014-03-26 2024-03-01 Julius-Maximilians-Universität Würzburg Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
ES2937167T3 (es) 2015-10-02 2023-03-24 Univ Wuerzburg J Maximilians Terapia de combinación que usa inhibidores de factor de crecimiento y diferenciación 15 (GDF-15) humano y bloqueadores del punto de control inmunitario
PE20211412A1 (es) 2018-08-20 2021-08-02 Pfizer Anticuerpos anti-gdf15, composiciones y metodos de uso

Also Published As

Publication number Publication date
KR20180054867A (ko) 2018-05-24
EP4321866A3 (en) 2024-03-20
JP2018535404A (ja) 2018-11-29
US20220242942A1 (en) 2022-08-04
AU2016333538A1 (en) 2018-04-26
US12473354B2 (en) 2025-11-18
CA3000290C (en) 2023-02-21
WO2017055612A1 (en) 2017-04-06
US11262360B2 (en) 2022-03-01
EP3356827A1 (en) 2018-08-08
DK3356827T3 (da) 2024-01-08
US20180292412A1 (en) 2018-10-11
EP3356827B1 (en) 2023-12-06
EP4321866A2 (en) 2024-02-14
FI3356827T3 (fi) 2024-01-03
KR102621034B1 (ko) 2024-01-03
CA3000290A1 (en) 2017-04-06
ES2968226T3 (es) 2024-05-08
AU2016333538B2 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JP6858181B2 (ja) 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５
JP7443298B2 (ja) ヒト成長分化因子１５（ｇｄｆ－１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
US20200386758A1 (en) Gdf-15 as a diagnostic marker for melanoma
EA044887B1 (ru) Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
HK1256067B (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
BR122025013944A2 (pt) Inibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201005

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210323

R150 Certificate of patent or registration of utility model

Ref document number: 6858181

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250